Immunex will receive $5.5 mil. and royalties on worldwide sales of IL-2 and PEG IL-2, the latter from Roche licensee Cetus. In addition, the settlement of a longstanding royalty dispute includes the repurchase by Roche of an Immunex option to manufacture IL-2 for sale by Roche in the U.S.
You may also be interested in...
The company has no development programs left in its R&D pipeline and will focus entirely on the commercialization of IBS drug Linzess while seeking late-stage assets from external sources.
The documents issued by the US agency on 29 September set slightly different accuracy standards, reflecting the increased fragility of hospital patients.
The US FDA commissioner published a blog post commending and highlighting the work device center staff have done during the pandemic to speed tests and devices to market to save lives.